Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
419 Leser
Artikel bewerten:
(2)

ITOCO Inc.: ITOCO INC to Acquire Biotech Protocols and Technology Related to Carbon Credit Generation From ECAPFIN S.A.P.I. DE C.V

Finanznachrichten News

TORONTO, ON / ACCESSWIRE / March 11, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that it has signed a purchase agreement with ECAPFIN S.A.P.I. De C.V. of Domicilio DISTRITO FEDERAL (Mexico City) Mexico, to acquire all the assets of the company which include:

  1. Bio Tech related to the growth and usage of the Nopal Cactus;
  2. Agreements to amalgamate Nopal Cactus Farms and related assets in Mexico and elsewhere for the purpose of creating commercial products including foods, and renewable bio-energy products;
  3. Technical knowledge related to applying for Carbon Credits that relate to Nopal's unique Carbon reducing properties.

ITOCO will conduct final due diligence on ECAPFIN's technology and contracts and the parties intend to close the acquisition transaction by June 30, 2021.

"We are very excited by the potential that ECAPFIN's technology and assets have in the green Bio-Tech space. We plan to leverage the Nopal plant's unique properties into several strong products that have significant environmental and land reclamation properties," said Michael Paul, CEO of ITOCO.

ITOCO will shortly announce several Board appointees relative to this announcement as well as a detailed and dedicated web page section related to this acquisition. Please see - www.itoco.net.

About ITOCO INC.
ITOCO's mission is to be a global leader in developing, distributing, and producing Bio Tech related technologies and methodologies in a compliant environmentally friendly manner. ITOCO INC. trades on the OTC Markets, symbol: ITMC. ITOCO is a 13-year-old publicly quoted specialty Bio Tech development, production and distribution company based in Toronto, Canada and Nevada USA. Itoco seeks to partner with outstanding individuals and companies within this field to joint venture, research, and co-develop Bio Tech related products and technologies to the market.

About ECAPFIN S.A.P.I DE C.V.
ECAPFIN is creating an effective solution for the capture and processing of CO2 as well as to generate clean energy from Nopal Cactus. Designed, developed, tested, it is a surprisingly profitable solution. In additional, the carbon sequestration achieved by the nopal cactus plantations results in biological carbon sequestration. Because cactus transform CO2 into calcium carbonate rather than storing CO2 into its biomass and that the captured CO2 is injected into the ground through root system of the plant, this type of carbon capture and storage can be assimilated to a permanent sequestration and, therefore, lead to the allowance of carbon offsets. Eco-Plan PLC is conceived to globally exploit the "Nopaltilla technology" under the name Eco-Plan to capture in a highly efficient way the CO2 emitted by industry and fossil fuel, therefore benefiting the environment and ecosystems. The team of Scientist is committed worldwide to climate protection through implementation of the Eco-plan technology and the offsetting of greenhouse gas emissions.

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, potential, intends, plans, hopes, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

CONTACT:
ITOCO INC.
Michael Paul, President & CEO
ir@ITOCO.net
+1 (905) 829-5000
www.itoco.net

SOURCE: ITOCO INC.



View source version on accesswire.com:
https://www.accesswire.com/634541/ITOCO-INC-to-Acquire-Biotech-Protocols-and-Technology-Related-to-Carbon-Credit-Generation-From-ECAPFIN-SAPI-DE-CV

© 2021 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.